Analytical performance and clinical utility of the INNOTEST® PHOSPHO-TAU(181P) assay for discrimination between Alzheimer's disease and dementia with Lewy bodies
Background: Total tau (T-tau) and β-amyloid(1-42) (Aβ1-42) levels in cerebrospinal fluid (CSF) can differentiate Alzheimer's disease (AD) from normal aging or depressive pseudo-dementia. Differential diagnosis from dementia with Lewy bodies (DLB) in clinical settings is difficult. Methods: The...
Gespeichert in:
| Veröffentlicht in: | Clinical chemistry and laboratory medicine 2006-12, Vol.44 (12), p.1472-1480 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1480 |
|---|---|
| container_issue | 12 |
| container_start_page | 1472 |
| container_title | Clinical chemistry and laboratory medicine |
| container_volume | 44 |
| creator | Vanderstichele, Hugo De Vreese, Karen Blennow, Kaj Andreasen, Niels Sindic, Christian Ivanoiu, Adrian Hampel, Harald Bürger, Katharina Parnetti, Lucilla Lanari, Alessia Padovani, Allesandro DiLuca, Monica Bläser, Miriam Ohrfelt Olsson, Annika Pottel, Hans Hulstaert, Frank Vanmechelen, Eugeen |
| description | Background: Total tau (T-tau) and β-amyloid(1-42) (Aβ1-42) levels in cerebrospinal fluid (CSF) can differentiate Alzheimer's disease (AD) from normal aging or depressive pseudo-dementia. Differential diagnosis from dementia with Lewy bodies (DLB) in clinical settings is difficult. Methods: The analytical performance of the INNOTEST® PHOSPHO-TAU(181P) assay was validated in terms of selectivity, sensitivity, specificity, precision, robustness, and stability. Clinical utility of the assay alone, or combined with T-tau and Aβ1-42, for discrimination of AD (n=94) from patients suffering from DLB (n=60) or from age-matched control subjects (CS) (n=60) was assessed in a multicenter study. Results: CSF concentrations of tau phosphorylated at threonine 181 (P-tau181P) in AD was significantly higher than in DLB and CS. Discriminant analysis, a classification tree, and logistic regression showed that P-tau181P was the most statistically significant single variable of the three biomarkers for discrimination between AD and DLB. Conclusions: P-tau181P quantification is a robust and reliable assay that may be useful in discriminating AD from DLB. Clin Chem Lab Med 2006;44:1472–80. |
| doi_str_mv | 10.1515/CCLM.2006.258 |
| format | Article |
| fullrecord | <record><control><sourceid>walterdegruyter_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_572539</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1515_CCLM_2006_25844121472</sourcerecordid><originalsourceid>FETCH-LOGICAL-c436t-f97fb9f540388df1e5ae768f1abcb0e6dd0b8f35e87e1c5e663e0c013e1d8b363</originalsourceid><addsrcrecordid>eNptkc1u1DAUhSMEEqWwZO8NAhYZ7Dj-mQWLUVRoRegUOpW6s5zkmnGbSUa2RyF9nD4AD8GT4XSqzoaF5SP7u-de3ZMkbwmeEUbYp6Iov88yjPksY_JZckRyKtKcUvL8Qecp5xl5mbzy_gZjwlgujpL7RafbMdhat2gLzvRuo7sakO4aVLe2e_jYBdvaMKLeoLAGdHZ-vlydXK7-_kEXp8vLeNLV4uoDkeTiI9Le6xFFH9RYXzu7sZ0Otu9QBWEA6NCivVuD3YB77ycEtN93a2ADXbAaDTasUQnDiKq-seBfJy-Mbj28ebyPk6svJ6viNC2XX8-KRZnWOeUhNXNhqrlhOaZSNoYA0yC4NERXdYWBNw2upKEMpABSM-CcAq4xoUAaWVFOj5N07-sH2O4qtY3DazeqXlv1-HQbFSgmMkbnB752vfcOzFMFwWoKRE2BqCkQFQOJ_Ls9v9U-btW4uGjrD0WSSibkxH3ec4NuA7gGfrndGIW66XcupuX_75_nJCO5yA5zWR_g95O_dreKCyqY-rHK1fXP629lIbAq6T_clbDV</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Analytical performance and clinical utility of the INNOTEST® PHOSPHO-TAU(181P) assay for discrimination between Alzheimer's disease and dementia with Lewy bodies</title><source>De Gruyter journals</source><creator>Vanderstichele, Hugo ; De Vreese, Karen ; Blennow, Kaj ; Andreasen, Niels ; Sindic, Christian ; Ivanoiu, Adrian ; Hampel, Harald ; Bürger, Katharina ; Parnetti, Lucilla ; Lanari, Alessia ; Padovani, Allesandro ; DiLuca, Monica ; Bläser, Miriam ; Ohrfelt Olsson, Annika ; Pottel, Hans ; Hulstaert, Frank ; Vanmechelen, Eugeen</creator><creatorcontrib>Vanderstichele, Hugo ; De Vreese, Karen ; Blennow, Kaj ; Andreasen, Niels ; Sindic, Christian ; Ivanoiu, Adrian ; Hampel, Harald ; Bürger, Katharina ; Parnetti, Lucilla ; Lanari, Alessia ; Padovani, Allesandro ; DiLuca, Monica ; Bläser, Miriam ; Ohrfelt Olsson, Annika ; Pottel, Hans ; Hulstaert, Frank ; Vanmechelen, Eugeen</creatorcontrib><description>Background: Total tau (T-tau) and β-amyloid(1-42) (Aβ1-42) levels in cerebrospinal fluid (CSF) can differentiate Alzheimer's disease (AD) from normal aging or depressive pseudo-dementia. Differential diagnosis from dementia with Lewy bodies (DLB) in clinical settings is difficult. Methods: The analytical performance of the INNOTEST® PHOSPHO-TAU(181P) assay was validated in terms of selectivity, sensitivity, specificity, precision, robustness, and stability. Clinical utility of the assay alone, or combined with T-tau and Aβ1-42, for discrimination of AD (n=94) from patients suffering from DLB (n=60) or from age-matched control subjects (CS) (n=60) was assessed in a multicenter study. Results: CSF concentrations of tau phosphorylated at threonine 181 (P-tau181P) in AD was significantly higher than in DLB and CS. Discriminant analysis, a classification tree, and logistic regression showed that P-tau181P was the most statistically significant single variable of the three biomarkers for discrimination between AD and DLB. Conclusions: P-tau181P quantification is a robust and reliable assay that may be useful in discriminating AD from DLB. Clin Chem Lab Med 2006;44:1472–80.</description><identifier>ISSN: 1434-6621</identifier><identifier>EISSN: 1437-4331</identifier><identifier>DOI: 10.1515/CCLM.2006.258</identifier><language>eng</language><publisher>Berlin: Walter de Gruyter</publisher><subject>Alzheimer's disease ; Biological and medical sciences ; cerebrospinal fluid ; dementia ; diagnosis ; General aspects ; Investigative techniques, diagnostic techniques (general aspects) ; Medical sciences ; P-tau ; P-tau181P</subject><ispartof>Clinical chemistry and laboratory medicine, 2006-12, Vol.44 (12), p.1472-1480</ispartof><rights>2007 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c436t-f97fb9f540388df1e5ae768f1abcb0e6dd0b8f35e87e1c5e663e0c013e1d8b363</citedby><cites>FETCH-LOGICAL-c436t-f97fb9f540388df1e5ae768f1abcb0e6dd0b8f35e87e1c5e663e0c013e1d8b363</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.degruyter.com/document/doi/10.1515/CCLM.2006.258/pdf$$EPDF$$P50$$Gwalterdegruyter$$H</linktopdf><linktohtml>$$Uhttps://www.degruyter.com/document/doi/10.1515/CCLM.2006.258/html$$EHTML$$P50$$Gwalterdegruyter$$H</linktohtml><link.rule.ids>230,314,778,782,883,27911,27912,66509,68293</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18385788$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:1946479$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Vanderstichele, Hugo</creatorcontrib><creatorcontrib>De Vreese, Karen</creatorcontrib><creatorcontrib>Blennow, Kaj</creatorcontrib><creatorcontrib>Andreasen, Niels</creatorcontrib><creatorcontrib>Sindic, Christian</creatorcontrib><creatorcontrib>Ivanoiu, Adrian</creatorcontrib><creatorcontrib>Hampel, Harald</creatorcontrib><creatorcontrib>Bürger, Katharina</creatorcontrib><creatorcontrib>Parnetti, Lucilla</creatorcontrib><creatorcontrib>Lanari, Alessia</creatorcontrib><creatorcontrib>Padovani, Allesandro</creatorcontrib><creatorcontrib>DiLuca, Monica</creatorcontrib><creatorcontrib>Bläser, Miriam</creatorcontrib><creatorcontrib>Ohrfelt Olsson, Annika</creatorcontrib><creatorcontrib>Pottel, Hans</creatorcontrib><creatorcontrib>Hulstaert, Frank</creatorcontrib><creatorcontrib>Vanmechelen, Eugeen</creatorcontrib><title>Analytical performance and clinical utility of the INNOTEST® PHOSPHO-TAU(181P) assay for discrimination between Alzheimer's disease and dementia with Lewy bodies</title><title>Clinical chemistry and laboratory medicine</title><addtitle>Clinical Chemical Laboratory Medicine</addtitle><description>Background: Total tau (T-tau) and β-amyloid(1-42) (Aβ1-42) levels in cerebrospinal fluid (CSF) can differentiate Alzheimer's disease (AD) from normal aging or depressive pseudo-dementia. Differential diagnosis from dementia with Lewy bodies (DLB) in clinical settings is difficult. Methods: The analytical performance of the INNOTEST® PHOSPHO-TAU(181P) assay was validated in terms of selectivity, sensitivity, specificity, precision, robustness, and stability. Clinical utility of the assay alone, or combined with T-tau and Aβ1-42, for discrimination of AD (n=94) from patients suffering from DLB (n=60) or from age-matched control subjects (CS) (n=60) was assessed in a multicenter study. Results: CSF concentrations of tau phosphorylated at threonine 181 (P-tau181P) in AD was significantly higher than in DLB and CS. Discriminant analysis, a classification tree, and logistic regression showed that P-tau181P was the most statistically significant single variable of the three biomarkers for discrimination between AD and DLB. Conclusions: P-tau181P quantification is a robust and reliable assay that may be useful in discriminating AD from DLB. Clin Chem Lab Med 2006;44:1472–80.</description><subject>Alzheimer's disease</subject><subject>Biological and medical sciences</subject><subject>cerebrospinal fluid</subject><subject>dementia</subject><subject>diagnosis</subject><subject>General aspects</subject><subject>Investigative techniques, diagnostic techniques (general aspects)</subject><subject>Medical sciences</subject><subject>P-tau</subject><subject>P-tau181P</subject><issn>1434-6621</issn><issn>1437-4331</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><recordid>eNptkc1u1DAUhSMEEqWwZO8NAhYZ7Dj-mQWLUVRoRegUOpW6s5zkmnGbSUa2RyF9nD4AD8GT4XSqzoaF5SP7u-de3ZMkbwmeEUbYp6Iov88yjPksY_JZckRyKtKcUvL8Qecp5xl5mbzy_gZjwlgujpL7RafbMdhat2gLzvRuo7sakO4aVLe2e_jYBdvaMKLeoLAGdHZ-vlydXK7-_kEXp8vLeNLV4uoDkeTiI9Le6xFFH9RYXzu7sZ0Otu9QBWEA6NCivVuD3YB77ycEtN93a2ADXbAaDTasUQnDiKq-seBfJy-Mbj28ebyPk6svJ6viNC2XX8-KRZnWOeUhNXNhqrlhOaZSNoYA0yC4NERXdYWBNw2upKEMpABSM-CcAq4xoUAaWVFOj5N07-sH2O4qtY3DazeqXlv1-HQbFSgmMkbnB752vfcOzFMFwWoKRE2BqCkQFQOJ_Ls9v9U-btW4uGjrD0WSSibkxH3ec4NuA7gGfrndGIW66XcupuX_75_nJCO5yA5zWR_g95O_dreKCyqY-rHK1fXP629lIbAq6T_clbDV</recordid><startdate>20061201</startdate><enddate>20061201</enddate><creator>Vanderstichele, Hugo</creator><creator>De Vreese, Karen</creator><creator>Blennow, Kaj</creator><creator>Andreasen, Niels</creator><creator>Sindic, Christian</creator><creator>Ivanoiu, Adrian</creator><creator>Hampel, Harald</creator><creator>Bürger, Katharina</creator><creator>Parnetti, Lucilla</creator><creator>Lanari, Alessia</creator><creator>Padovani, Allesandro</creator><creator>DiLuca, Monica</creator><creator>Bläser, Miriam</creator><creator>Ohrfelt Olsson, Annika</creator><creator>Pottel, Hans</creator><creator>Hulstaert, Frank</creator><creator>Vanmechelen, Eugeen</creator><general>Walter de Gruyter</general><general>De Gruyter</general><scope>BSCLL</scope><scope>IQODW</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ADTPV</scope><scope>AOWAS</scope></search><sort><creationdate>20061201</creationdate><title>Analytical performance and clinical utility of the INNOTEST® PHOSPHO-TAU(181P) assay for discrimination between Alzheimer's disease and dementia with Lewy bodies</title><author>Vanderstichele, Hugo ; De Vreese, Karen ; Blennow, Kaj ; Andreasen, Niels ; Sindic, Christian ; Ivanoiu, Adrian ; Hampel, Harald ; Bürger, Katharina ; Parnetti, Lucilla ; Lanari, Alessia ; Padovani, Allesandro ; DiLuca, Monica ; Bläser, Miriam ; Ohrfelt Olsson, Annika ; Pottel, Hans ; Hulstaert, Frank ; Vanmechelen, Eugeen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c436t-f97fb9f540388df1e5ae768f1abcb0e6dd0b8f35e87e1c5e663e0c013e1d8b363</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Alzheimer's disease</topic><topic>Biological and medical sciences</topic><topic>cerebrospinal fluid</topic><topic>dementia</topic><topic>diagnosis</topic><topic>General aspects</topic><topic>Investigative techniques, diagnostic techniques (general aspects)</topic><topic>Medical sciences</topic><topic>P-tau</topic><topic>P-tau181P</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vanderstichele, Hugo</creatorcontrib><creatorcontrib>De Vreese, Karen</creatorcontrib><creatorcontrib>Blennow, Kaj</creatorcontrib><creatorcontrib>Andreasen, Niels</creatorcontrib><creatorcontrib>Sindic, Christian</creatorcontrib><creatorcontrib>Ivanoiu, Adrian</creatorcontrib><creatorcontrib>Hampel, Harald</creatorcontrib><creatorcontrib>Bürger, Katharina</creatorcontrib><creatorcontrib>Parnetti, Lucilla</creatorcontrib><creatorcontrib>Lanari, Alessia</creatorcontrib><creatorcontrib>Padovani, Allesandro</creatorcontrib><creatorcontrib>DiLuca, Monica</creatorcontrib><creatorcontrib>Bläser, Miriam</creatorcontrib><creatorcontrib>Ohrfelt Olsson, Annika</creatorcontrib><creatorcontrib>Pottel, Hans</creatorcontrib><creatorcontrib>Hulstaert, Frank</creatorcontrib><creatorcontrib>Vanmechelen, Eugeen</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>CrossRef</collection><collection>SwePub</collection><collection>SwePub Articles</collection><jtitle>Clinical chemistry and laboratory medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vanderstichele, Hugo</au><au>De Vreese, Karen</au><au>Blennow, Kaj</au><au>Andreasen, Niels</au><au>Sindic, Christian</au><au>Ivanoiu, Adrian</au><au>Hampel, Harald</au><au>Bürger, Katharina</au><au>Parnetti, Lucilla</au><au>Lanari, Alessia</au><au>Padovani, Allesandro</au><au>DiLuca, Monica</au><au>Bläser, Miriam</au><au>Ohrfelt Olsson, Annika</au><au>Pottel, Hans</au><au>Hulstaert, Frank</au><au>Vanmechelen, Eugeen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Analytical performance and clinical utility of the INNOTEST® PHOSPHO-TAU(181P) assay for discrimination between Alzheimer's disease and dementia with Lewy bodies</atitle><jtitle>Clinical chemistry and laboratory medicine</jtitle><addtitle>Clinical Chemical Laboratory Medicine</addtitle><date>2006-12-01</date><risdate>2006</risdate><volume>44</volume><issue>12</issue><spage>1472</spage><epage>1480</epage><pages>1472-1480</pages><issn>1434-6621</issn><eissn>1437-4331</eissn><abstract>Background: Total tau (T-tau) and β-amyloid(1-42) (Aβ1-42) levels in cerebrospinal fluid (CSF) can differentiate Alzheimer's disease (AD) from normal aging or depressive pseudo-dementia. Differential diagnosis from dementia with Lewy bodies (DLB) in clinical settings is difficult. Methods: The analytical performance of the INNOTEST® PHOSPHO-TAU(181P) assay was validated in terms of selectivity, sensitivity, specificity, precision, robustness, and stability. Clinical utility of the assay alone, or combined with T-tau and Aβ1-42, for discrimination of AD (n=94) from patients suffering from DLB (n=60) or from age-matched control subjects (CS) (n=60) was assessed in a multicenter study. Results: CSF concentrations of tau phosphorylated at threonine 181 (P-tau181P) in AD was significantly higher than in DLB and CS. Discriminant analysis, a classification tree, and logistic regression showed that P-tau181P was the most statistically significant single variable of the three biomarkers for discrimination between AD and DLB. Conclusions: P-tau181P quantification is a robust and reliable assay that may be useful in discriminating AD from DLB. Clin Chem Lab Med 2006;44:1472–80.</abstract><cop>Berlin</cop><cop>New York, NY</cop><pub>Walter de Gruyter</pub><doi>10.1515/CCLM.2006.258</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1434-6621 |
| ispartof | Clinical chemistry and laboratory medicine, 2006-12, Vol.44 (12), p.1472-1480 |
| issn | 1434-6621 1437-4331 |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_572539 |
| source | De Gruyter journals |
| subjects | Alzheimer's disease Biological and medical sciences cerebrospinal fluid dementia diagnosis General aspects Investigative techniques, diagnostic techniques (general aspects) Medical sciences P-tau P-tau181P |
| title | Analytical performance and clinical utility of the INNOTEST® PHOSPHO-TAU(181P) assay for discrimination between Alzheimer's disease and dementia with Lewy bodies |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T15%3A52%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-walterdegruyter_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Analytical%20performance%20and%20clinical%20utility%20of%20the%20INNOTEST%C2%AE%20PHOSPHO-TAU(181P)%20assay%20for%20discrimination%20between%20Alzheimer's%20disease%20and%20dementia%20with%20Lewy%20bodies&rft.jtitle=Clinical%20chemistry%20and%20laboratory%20medicine&rft.au=Vanderstichele,%20Hugo&rft.date=2006-12-01&rft.volume=44&rft.issue=12&rft.spage=1472&rft.epage=1480&rft.pages=1472-1480&rft.issn=1434-6621&rft.eissn=1437-4331&rft_id=info:doi/10.1515/CCLM.2006.258&rft_dat=%3Cwalterdegruyter_swepu%3E10_1515_CCLM_2006_25844121472%3C/walterdegruyter_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |